The former top vaccines official at the Food and Drug Administration criticized Health and Human Services Secretary Robert F.

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Workers who received Novavax reported 12.5% fewer local reactions than those who received the Pfizer vaccine. Average hours ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...